Trevena (TRVN) Misses Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. SPY
7. CVS
8. UNH
9. DAL
10. TMUS

Go back to Trevena (TRVN) Misses Q4 EPS by 4c

Trevena Reports Full Year 2015 Financial Results

March 9, 2016 7:00 AM EST

- Achieved significant clinical and regulatory milestones in CNS and AHF programs -

- Net loss for the year of $50.5 million, or $1.15 per share -

- Company to host conference call at 7:30 AM EST today -

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today announced financial results for the fourth quarter and full year ended December 31, 2015 and provided an... More